IPSEN (OTCMKTS:IPSEY) Stock Short Interest Climbs 3,378.0%

IPSEN (OTCMKTS:IPSEY) was the target of a significant increase in short interest during the month of September. As of September 30th, there was short interest totaling 1,426 shares, an increase of 3,378.0% from the September 15th total of 41 shares. Based on an average daily volume of 626 shares, the days-to-cover ratio is currently 2.3 days. Currently, 0.0% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Jefferies Financial Group lowered shares of IPSEN from a “hold” rating to a “moderate sell” rating in a research report on Sunday, August 2nd. HC Wainwright restated a “buy” rating on shares of IPSEN in a report on Tuesday, June 30th. Finally, Barclays upgraded shares of IPSEN from a “strong sell” rating to a “hold” rating in a report on Thursday, September 17th. Two research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, IPSEN presently has an average rating of “Hold”.

IPSEN Stock Up 1.3%

Shares of IPSEY stock traded up $0.50 during midday trading on Friday, reaching $40.65. 395 shares of the stock were exchanged, compared to its average volume of 2,037. The company’s 50 day moving average is $45.32 and its two-hundred day moving average is $46.31. IPSEN has a 1 year low of $32.68 and a 1 year high of $51.10.

About IPSEN

Ipsen SA is a France-based biopharmaceutical company focused on the discovery, development and commercialization of medicines in specialty care. Its principal therapeutic areas are oncology, rare diseases and neuroscience, with an emphasis on treatments for conditions that often have limited therapeutic options.

The company’s portfolio includes Somatuline (lanreotide) for certain neuroendocrine tumors and endocrine disorders, Dysport (abobotulinumtoxinA) for selected movement disorders and aesthetic applications, and cancer treatments such as Cabometyx and Onivyde.